Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10899969 | 0.96 | ANPEP (0.53) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL1237 | 0.96 | ANPEP (0.53) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL9814415 | 0.92 | ANPEP (0.50) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL51210 | 0.92 | ANPEP (0.50) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL3887127 | 0.92 | ANPEP (0.50) | ANPEPTSHRLMNATHRBALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28825800 | 0.92 | ANPEP (0.50) | ANPEPTSHRLMNATHRBALDH1A1 | |
| Potassium Ion SCHEMBL22426233 | 0.89 | ANPEP (0.47) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL2078883 | 0.89 | TSHR (0.47) | ANPEPTSHRLMNATHRBALDH1A1 | |
| Lithium Ion SCHEMBL22426275 | 0.89 | ANPEP (0.47) | ANPEPTSHRLMNATHRBALDH1A1 | |
| SCHEMBL88650 | 0.85 | TSHR (0.50) | ANPEPTSHRLMNATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314237-B2 | Preparation of 10-keto morphinans by benzylic oxidation | MALLINCKRODT LLC (US) | 2012-11-20 | — | — | US | claimed |
| WO-2011034747-A1 | PREPARATION OF 10-KETO MORPHINANS BY BENZYLIC OXIDATION | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | WO | claimed |
| US-20110071296-A1 | Preparation of 10-Keto Morphinans by Benzylic Oxidation | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | US | claimed |
| US-20250250216-A1 | CYCLIC COMPOUND HAVING IODINE ATOM | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | WASHINGTON UNIVERSITY | 2025-05-08 | — | — | US | disclosed |
| WO-2025033019-A1 | COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND PRODUCTION METHOD | 三菱瓦斯化学株式会社 | 2025-02-13 | — | — | WO | disclosed |
| US-20240383845-A1 | NAPHTHALENEDITHIOL AND DERIVATIVE THEREOF, AND PRODUCTION PROCESS AND USE FOR THE SAME | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024214321-A1 | COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND METHOD FOR PRODUCING SAME | 三菱瓦斯化学株式会社 | 2024-10-17 | — | — | WO | disclosed |
| US-12077559-B2 | Process for the preparation of 3α-hydroxy-5α-pregnan-20-one (brexanolone) | INDUSTRIALE CHIMICA S.R.L. (IT) | 2024-09-03 | — | — | US | disclosed |
| WO-2024135708-A1 | METHOD FOR PRODUCING COMPOUND, POLYMER, COMPOSITION, AND PATTERN FORMATION METHOD | 三菱瓦斯化学株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-4378928-A1 | NAPHTHALENE DITHIOL AND DERIVATIVE THEREOF, AND PRODUCTION METHODS AND USES FOR SAME | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2024-06-05 | — | — | EP | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5886035-A | PREVENTIVE AND THERAPEUTICAL MEDICINE FOR EYE DISEASE | ASAHI GLASS COMPANY LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0850926-A2 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS COMPANY LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
| US-4756742-A | Herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0092787-A1 | Process for the preparation of a phenylalkylaminoethylsalicylamide | SCHERING CORPORATION (US) | 1983-11-02 | — | — | EP | disclosed |
| EP-0009702-B1 | A PHENYLALKYLAMINOETHYLSALICYLAMIDE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | SCHERING CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| EP-0009702-A1 | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it | SCHERING CORPORATION (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071296-A1 | Preparation of 10-Keto Morphinans by Benzylic Oxidation | MB, AKR1B10, POR | ANPEP 3307/4885TSHR 4161/4885LMNA 923/4885 |
| US-20250250216-A1 | CYCLIC COMPOUND HAVING IODINE ATOM | IGF1R, SSTR1, CCNI | ANPEP 4602/4885TSHR 19/4885LMNA 3507/4885 |
| US-20240383845-A1 | NAPHTHALENEDITHIOL AND DERIVATIVE THEREOF, AND PRODUCTION PROCESS AND USE FOR THE SAME | HSD11B1, DHCR7, CYP17A1 | ANPEP 3675/4885TSHR 3628/4885LMNA 2311/4885 |
| US-12077559-B2 | Process for the preparation of 3α-hydroxy-5α-pregnan-20-one (brexanolone) | CYP17A1, HSD17B7, CYP21A2 | ANPEP 4603/4885TSHR 188/4885LMNA 3232/4885 |
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | ANPEP 4300/4885TSHR 204/4885LMNA 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.